BACKGROUND: Universal ganciclovir (GCV) prophylaxis is a strategy aimed at reducing cytomegalovirus (CMV) infection and delaying the development of bronchiolitis obliterans syndrome (BOS). However, the optimal duration of GCV prophylaxis remains unclear. We report our experience with GCV prophylaxis administered indefinitely and its effect on CMV pneumonitis, BOS and survival after lung transplantation (LT). METHODS: One hundred fifty-one patients surviving >100 days after LT were analyzed. GCV was given to 130 CMV donor- or recipient-seropositive patients. Data from 90 patients who received indefinite GCV prophylaxis (IND) and 40 patients who discontinued their GCV prophylaxis (STOP) were compared. RESULTS: CMV pneumonitis occurred in 16%, 8%, 17% and 19% of patients in the D+R+, D-R+, D+R- and D-R- groups, respectively. In the STOP cohort, 15 of 40 patients developed CMV pneumonitis (median time 79 days) after GCV was stopped. Ten of these 15 patients developed BOS (median time 116 days) after discontinuing GCV. The risk of CMV pneumonitis in the STOP cohort was significantly higher when GCV prophylaxis was discontinued within the first year. Cumulative incidence of CMV pneumonitis in the IND and STOP groups at 5 years was 2% and 57%, respectively (p < 0.001). BOS-free survival and survival were similar across both groups. CONCLUSIONS: Indefinite GCV prophylaxis prevents CMV pneumonitis in 98% of LT recipients. Thirty-eight percent of patients discontinuing prophylaxis developed CMV pneumonitis, 50% of whom progressed to BOS within 1 year. Continuing ganciclovir prophylaxis indefinitely after lung transplantation should be considered.
BACKGROUND: Universal ganciclovir (GCV) prophylaxis is a strategy aimed at reducing cytomegalovirus (CMV) infection and delaying the development of bronchiolitis obliterans syndrome (BOS). However, the optimal duration of GCV prophylaxis remains unclear. We report our experience with GCV prophylaxis administered indefinitely and its effect on CMV pneumonitis, BOS and survival after lung transplantation (LT). METHODS: One hundred fifty-one patients surviving >100 days after LT were analyzed. GCV was given to 130 CMV donor- or recipient-seropositive patients. Data from 90 patients who received indefinite GCV prophylaxis (IND) and 40 patients who discontinued their GCV prophylaxis (STOP) were compared. RESULTS: CMV pneumonitis occurred in 16%, 8%, 17% and 19% of patients in the D+R+, D-R+, D+R- and D-R- groups, respectively. In the STOP cohort, 15 of 40 patients developed CMV pneumonitis (median time 79 days) after GCV was stopped. Ten of these 15 patients developed BOS (median time 116 days) after discontinuing GCV. The risk of CMV pneumonitis in the STOP cohort was significantly higher when GCV prophylaxis was discontinued within the first year. Cumulative incidence of CMV pneumonitis in the IND and STOP groups at 5 years was 2% and 57%, respectively (p < 0.001). BOS-free survival and survival were similar across both groups. CONCLUSIONS: Indefinite GCV prophylaxis prevents CMV pneumonitis in 98% of LT recipients. Thirty-eight percent of patients discontinuing prophylaxis developed CMV pneumonitis, 50% of whom progressed to BOS within 1 year. Continuing ganciclovir prophylaxis indefinitely after lung transplantation should be considered.
Authors: Corinna La Rosa; Ajit P Limaye; Aparna Krishnan; Gideon Blumstein; Jeff Longmate; Don J Diamond Journal: Transpl Int Date: 2011-06-14 Impact factor: 3.782
Authors: Robin K Avery; Fernanda P Silveira; Kaitlin Benedict; Angela A Cleveland; Carol A Kauffman; Mindy G Schuster; Erik R Dubberke; Shahid Husain; David L Paterson; Tom Chiller; Peter Pappas Journal: Transpl Infect Dis Date: 2018-03-30 Impact factor: 2.228
Authors: Laurie D Snyder; C Ashley Finlen-Copeland; W Jackson Turbyfill; David Howell; Daniel A Willner; Scott M Palmer Journal: Am J Respir Crit Care Med Date: 2010-02-18 Impact factor: 21.405
Authors: Kavitha Ranganathan; Sarah Worley; Marian G Michaels; Susana Arrigan; Paul Aurora; Manfred Ballmann; Debra Boyer; Carol Conrad; Irmgard Eichler; Okan Elidemir; Samuel Goldfarb; George B Mallory; Peter J Mogayzel; Daiva Parakininkas; Melinda Solomon; Gary Visner; Stuart C Sweet; Albert Faro; Lara Danziger-Isakov Journal: J Heart Lung Transplant Date: 2009-10 Impact factor: 10.247
Authors: Lucio R Minces; M Hong Nguyen; Dimitra Mitsani; Ryan K Shields; Eun J Kwak; Fernanda P Silveira; Rima Abdel-Massih; Joseph M Pilewski; Maria M Crespo; Christian Bermudez; Jay K Bhama; Yoshiya Toyoda; Cornelius J Clancy Journal: Antimicrob Agents Chemother Date: 2013-10-21 Impact factor: 5.191
Authors: Martina Schneider; Teresa Matiqi; Michael Kundi; Franz J J Rieder; Martin Andreas; Robert Strassl; Andreas Zuckermann; Christof Jungbauer; Christoph Steininger Journal: J Clin Virol Date: 2016-10-04 Impact factor: 3.168
Authors: Nicole N Haese; Jennifer M Burg; Takeshi F Andoh; Iris K A Jones; Craig N Kreklywich; Patricia P Smith; Susan L Orloff; Daniel N Streblow Journal: Transpl Infect Dis Date: 2020-12-07 Impact factor: 2.228